Latest Breaking News On - Nevan charles elam - Page 1 : comparemela.com

Rezolute's oral Eylea rival hits phase 2 goal, sending stock up

Rezolute's oral Eylea rival hits phase 2 goal, sending stock up
fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.

Brian-roberts
Nevan-charles-elam
Medical-officer-brian-roberts
Charles-elam

Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update

Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Christen-baglaneas
Daron-evans
Stephanie-carrington
Nevan-charles-elam
Access-program
European-medicines-agency
Rezolute-inc
Securities-exchange
Regulatory-agency
Nasdaq
Reports-second-quarter-fiscal

Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update

13.02.2024 - Phase 3 clinical study of RZ358 underway in patients with congenital hyperinsulinism (cHI); topline results expected in mid-2025 Benefit shown in individual patient cases with RZ358 for tumor-associated hyperinsulinism (taHI) under Expanded Access .

Christen-baglaneas
Nevan-charles-elam
Daron-evans
Stephanie-carrington
Regulatory-agency
Nasdaq
European-medicines-agency
Securities-exchange
Rezolute-inc
Access-program
Chief-executive-officer

Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer

REDWOOD CITY, Calif., Jan. 24, 2024 Rezolute, Inc. , a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare.

Rice-university
Texas
United-states
Daron-evan
Christen-baglaneas
Nevan-charles-elam
Stephanie-carrington
Daron-evans
University-of-texas-at-arlington
Fuqua-school-of-business-at-duke-university
Securities-exchange
Master-of-business-administration

Rezolute Initiates Phase 3 Clinical Study for RZ358 in Congenital Hyperinsulinism

REDWOOD CITY, Calif., Dec. 14, 2023 (GLOBE NEWSWIRE) Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today

Stephanie-carrington
Nevan-charles-elam
Rezolute-inc
Nasdaq
Securities-exchange
European-medicines-agency
Chief-executive-officer
Securities-act
Securities-exchange-act
Private-securities-litigation-reform-act
Risk-factors
Annual-report